| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoarthritis, Knee | 20 | 2021 | 169 | 4.430 |
Why?
|
| Lupus Erythematosus, Systemic | 21 | 2021 | 100 | 4.190 |
Why?
|
| Osteoarthritis | 12 | 2021 | 168 | 2.440 |
Why?
|
| Arthritis, Rheumatoid | 13 | 2020 | 132 | 2.350 |
Why?
|
| Quality of Life | 11 | 2018 | 261 | 2.030 |
Why?
|
| Humans | 99 | 2022 | 12240 | 1.940 |
Why?
|
| Myositis | 5 | 2015 | 15 | 1.860 |
Why?
|
| Creatine Kinase | 5 | 2015 | 17 | 1.830 |
Why?
|
| Knee Joint | 12 | 2019 | 284 | 1.730 |
Why?
|
| Middle Aged | 52 | 2021 | 4043 | 1.630 |
Why?
|
| Osteoarthritis, Hip | 8 | 2020 | 38 | 1.620 |
Why?
|
| Female | 61 | 2021 | 6974 | 1.620 |
Why?
|
| Rheumatic Diseases | 4 | 2021 | 30 | 1.520 |
Why?
|
| Arthralgia | 4 | 2019 | 56 | 1.490 |
Why?
|
| Rheumatology | 7 | 2022 | 42 | 1.430 |
Why?
|
| Male | 54 | 2019 | 6815 | 1.380 |
Why?
|
| Severity of Illness Index | 16 | 2018 | 423 | 1.250 |
Why?
|
| Adult | 40 | 2019 | 3557 | 1.240 |
Why?
|
| Disease Management | 3 | 2021 | 59 | 1.200 |
Why?
|
| Body Image | 4 | 2014 | 19 | 1.180 |
Why?
|
| Gait | 12 | 2019 | 195 | 1.110 |
Why?
|
| Pain | 9 | 2019 | 193 | 1.070 |
Why?
|
| Arthritis, Psoriatic | 3 | 2017 | 11 | 1.040 |
Why?
|
| Pain Measurement | 8 | 2019 | 211 | 1.010 |
Why?
|
| Surveys and Questionnaires | 8 | 2018 | 546 | 0.940 |
Why?
|
| Rheumatologists | 4 | 2020 | 13 | 0.870 |
Why?
|
| Aspartate Aminotransferases | 2 | 2015 | 10 | 0.870 |
Why?
|
| Alanine Transaminase | 2 | 2015 | 10 | 0.870 |
Why?
|
| Health Status | 8 | 2018 | 96 | 0.840 |
Why?
|
| Hyaluronic Acid | 2 | 2019 | 23 | 0.830 |
Why?
|
| Antirheumatic Agents | 5 | 2020 | 40 | 0.810 |
Why?
|
| Lupus Erythematosus, Cutaneous | 2 | 2014 | 4 | 0.810 |
Why?
|
| Aged | 26 | 2021 | 4000 | 0.810 |
Why?
|
| Antibodies, Monoclonal | 4 | 2017 | 86 | 0.780 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2018 | 165 | 0.770 |
Why?
|
| Muscle Strength | 5 | 2019 | 46 | 0.760 |
Why?
|
| Bone Density | 6 | 2011 | 110 | 0.760 |
Why?
|
| Reproducibility of Results | 10 | 2021 | 324 | 0.740 |
Why?
|
| Arthritis, Infectious | 2 | 2017 | 32 | 0.720 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2021 | 7 | 0.700 |
Why?
|
| Lupus Nephritis | 1 | 2021 | 15 | 0.690 |
Why?
|
| Immunosuppressive Agents | 4 | 2017 | 61 | 0.680 |
Why?
|
| Data Interpretation, Statistical | 1 | 2021 | 40 | 0.670 |
Why?
|
| Shoes | 2 | 2013 | 13 | 0.660 |
Why?
|
| Weight-Bearing | 10 | 2014 | 72 | 0.650 |
Why?
|
| Cartilage, Articular | 3 | 2021 | 163 | 0.650 |
Why?
|
| Research Design | 1 | 2021 | 79 | 0.640 |
Why?
|
| Analgesics | 2 | 2020 | 48 | 0.640 |
Why?
|
| Tuberculosis | 3 | 2009 | 12 | 0.640 |
Why?
|
| Nerve Growth Factor | 2 | 2017 | 25 | 0.640 |
Why?
|
| Leg | 4 | 2008 | 16 | 0.640 |
Why?
|
| Musculoskeletal Pain | 1 | 2020 | 13 | 0.620 |
Why?
|
| Etanercept | 4 | 2017 | 8 | 0.620 |
Why?
|
| Nerve Growth Factors | 1 | 2020 | 17 | 0.620 |
Why?
|
| Analgesics, Non-Narcotic | 3 | 2017 | 14 | 0.590 |
Why?
|
| Cross-Sectional Studies | 10 | 2019 | 400 | 0.580 |
Why?
|
| Vibration | 4 | 2018 | 18 | 0.570 |
Why?
|
| Patient Acuity | 1 | 2018 | 5 | 0.560 |
Why?
|
| Hip Joint | 4 | 2004 | 136 | 0.530 |
Why?
|
| Retrospective Studies | 10 | 2018 | 1467 | 0.530 |
Why?
|
| Treatment Outcome | 9 | 2019 | 1478 | 0.510 |
Why?
|
| Dermatomyositis | 2 | 2014 | 5 | 0.510 |
Why?
|
| Hepatitis C, Chronic | 1 | 2017 | 18 | 0.510 |
Why?
|
| Chondrosarcoma | 10 | 2006 | 17 | 0.480 |
Why?
|
| Mortality, Premature | 1 | 2015 | 5 | 0.450 |
Why?
|
| Prednisone | 1 | 2015 | 31 | 0.450 |
Why?
|
| Methylprednisolone | 1 | 2015 | 10 | 0.450 |
Why?
|
| Joints | 3 | 2008 | 43 | 0.450 |
Why?
|
| Biomechanical Phenomena | 7 | 2013 | 297 | 0.440 |
Why?
|
| Orthotic Devices | 3 | 2010 | 16 | 0.440 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 39 | 0.440 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 55 | 0.440 |
Why?
|
| Proprioception | 1 | 2014 | 8 | 0.430 |
Why?
|
| Exercise Therapy | 3 | 2020 | 42 | 0.420 |
Why?
|
| Health Status Indicators | 2 | 2016 | 38 | 0.420 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 64 | 0.420 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2014 | 1 | 0.420 |
Why?
|
| Keratan Sulfate | 3 | 2006 | 12 | 0.420 |
Why?
|
| United States | 8 | 2020 | 989 | 0.410 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 2014 | 2 | 0.410 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 25 | 0.410 |
Why?
|
| Immunoglobulin G | 3 | 2009 | 38 | 0.390 |
Why?
|
| Foot Orthoses | 1 | 2013 | 5 | 0.390 |
Why?
|
| Vasculitis | 2 | 2009 | 17 | 0.390 |
Why?
|
| Dermatology | 1 | 2012 | 3 | 0.380 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2012 | 6 | 0.370 |
Why?
|
| Radiography | 6 | 2010 | 258 | 0.340 |
Why?
|
| Touch | 2 | 2008 | 7 | 0.340 |
Why?
|
| Synovial Fluid | 3 | 2011 | 53 | 0.330 |
Why?
|
| Benchmarking | 1 | 2010 | 13 | 0.320 |
Why?
|
| Knee | 1 | 2010 | 16 | 0.320 |
Why?
|
| Quadriceps Muscle | 1 | 2010 | 16 | 0.320 |
Why?
|
| Foot | 1 | 2010 | 17 | 0.310 |
Why?
|
| Hand Joints | 2 | 2020 | 2 | 0.310 |
Why?
|
| Demography | 1 | 2010 | 37 | 0.310 |
Why?
|
| Income | 1 | 2010 | 35 | 0.310 |
Why?
|
| Biomarkers | 5 | 2017 | 294 | 0.300 |
Why?
|
| Isoniazid | 1 | 2009 | 2 | 0.300 |
Why?
|
| Transaminases | 1 | 2009 | 4 | 0.300 |
Why?
|
| Methotrexate | 1 | 2009 | 18 | 0.300 |
Why?
|
| Risk Factors | 5 | 2021 | 1049 | 0.300 |
Why?
|
| Psychometrics | 5 | 2018 | 95 | 0.290 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2009 | 11 | 0.290 |
Why?
|
| Liver | 1 | 2009 | 57 | 0.290 |
Why?
|
| Disease Progression | 6 | 2013 | 290 | 0.280 |
Why?
|
| Pilot Projects | 3 | 2014 | 214 | 0.270 |
Why?
|
| Language | 3 | 2021 | 30 | 0.270 |
Why?
|
| Immunoconjugates | 1 | 2008 | 6 | 0.270 |
Why?
|
| Arthritis, Experimental | 2 | 2019 | 30 | 0.260 |
Why?
|
| Range of Motion, Articular | 4 | 2019 | 278 | 0.260 |
Why?
|
| Walking | 1 | 2008 | 108 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 179 | 0.260 |
Why?
|
| Cohort Studies | 5 | 2019 | 827 | 0.260 |
Why?
|
| Joint Deformities, Acquired | 1 | 2007 | 1 | 0.260 |
Why?
|
| Reference Values | 3 | 2014 | 103 | 0.250 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 46 | 0.240 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2006 | 39 | 0.230 |
Why?
|
| Glucocorticoids | 3 | 2018 | 35 | 0.230 |
Why?
|
| Pain Management | 3 | 2018 | 74 | 0.230 |
Why?
|
| Sensory Thresholds | 3 | 2012 | 13 | 0.230 |
Why?
|
| Femur Head Necrosis | 1 | 2005 | 2 | 0.220 |
Why?
|
| Bone Neoplasms | 5 | 2004 | 59 | 0.220 |
Why?
|
| Case-Control Studies | 3 | 2014 | 256 | 0.210 |
Why?
|
| Immunocompromised Host | 3 | 2021 | 25 | 0.210 |
Why?
|
| Polymyositis | 2 | 2014 | 5 | 0.210 |
Why?
|
| Cross-Cultural Comparison | 3 | 2013 | 20 | 0.200 |
Why?
|
| Proteoglycans | 3 | 1994 | 59 | 0.200 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2005 | 349 | 0.200 |
Why?
|
| Risk Assessment | 4 | 2014 | 295 | 0.200 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 218 | 0.200 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2003 | 4 | 0.200 |
Why?
|
| Chi-Square Distribution | 3 | 2014 | 60 | 0.200 |
Why?
|
| Diclofenac | 1 | 2003 | 2 | 0.190 |
Why?
|
| Acetaminophen | 1 | 2003 | 11 | 0.190 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 2152 | 0.190 |
Why?
|
| Animals | 5 | 2020 | 2092 | 0.190 |
Why?
|
| Socioeconomic Factors | 3 | 2015 | 153 | 0.190 |
Why?
|
| Kidney | 1 | 2003 | 87 | 0.190 |
Why?
|
| Pneumococcal Infections | 1 | 2021 | 4 | 0.180 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2021 | 4 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2008 | 95 | 0.170 |
Why?
|
| Cartilage | 2 | 1992 | 41 | 0.170 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 726 | 0.170 |
Why?
|
| Medication Therapy Management | 1 | 2021 | 1 | 0.170 |
Why?
|
| Patient Care Planning | 1 | 2021 | 15 | 0.170 |
Why?
|
| Internship and Residency | 1 | 2022 | 103 | 0.160 |
Why?
|
| Foundations | 1 | 2020 | 1 | 0.160 |
Why?
|
| Mycobacterium Infections | 1 | 2019 | 2 | 0.150 |
Why?
|
| Mycobacterium haemophilum | 1 | 2019 | 2 | 0.150 |
Why?
|
| Mediastinal Diseases | 1 | 2019 | 3 | 0.150 |
Why?
|
| Chicago | 3 | 2018 | 453 | 0.150 |
Why?
|
| Adjuvants, Immunologic | 1 | 2019 | 4 | 0.150 |
Why?
|
| Injections, Intra-Articular | 1 | 2019 | 31 | 0.150 |
Why?
|
| Azacitidine | 1 | 2019 | 9 | 0.150 |
Why?
|
| Young Adult | 4 | 2015 | 863 | 0.150 |
Why?
|
| Chronic Pain | 1 | 2020 | 63 | 0.150 |
Why?
|
| Absorptiometry, Photon | 4 | 2011 | 62 | 0.150 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 75 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 116 | 0.150 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2018 | 7 | 0.140 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 13 | 0.140 |
Why?
|
| Observer Variation | 1 | 2018 | 47 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 14 | 0.140 |
Why?
|
| DNA Methylation | 1 | 2019 | 93 | 0.140 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 58 | 0.140 |
Why?
|
| Prognosis | 4 | 2017 | 363 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 71 | 0.140 |
Why?
|
| Antibodies, Antinuclear | 2 | 2017 | 6 | 0.140 |
Why?
|
| Arthroplasty | 1 | 1998 | 54 | 0.140 |
Why?
|
| Hyperalgesia | 1 | 2018 | 33 | 0.140 |
Why?
|
| Time Factors | 5 | 2017 | 695 | 0.130 |
Why?
|
| Liver Function Tests | 1 | 2017 | 12 | 0.130 |
Why?
|
| Age Factors | 2 | 2012 | 350 | 0.130 |
Why?
|
| Sex Factors | 4 | 2018 | 229 | 0.130 |
Why?
|
| Statistics as Topic | 1 | 2017 | 51 | 0.130 |
Why?
|
| Viral Load | 1 | 2017 | 43 | 0.130 |
Why?
|
| United Kingdom | 2 | 2010 | 23 | 0.130 |
Why?
|
| Stress, Mechanical | 2 | 2007 | 86 | 0.130 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 16 | 0.130 |
Why?
|
| Linear Models | 2 | 2014 | 115 | 0.130 |
Why?
|
| Adolescent | 5 | 2015 | 989 | 0.120 |
Why?
|
| Depression | 1 | 2019 | 229 | 0.120 |
Why?
|
| Arthritis, Juvenile | 2 | 2009 | 6 | 0.120 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2009 | 11 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 68 | 0.120 |
Why?
|
| Fatigue | 1 | 2016 | 25 | 0.120 |
Why?
|
| Chondrocytes | 3 | 2007 | 58 | 0.120 |
Why?
|
| Safety-net Providers | 1 | 2015 | 5 | 0.110 |
Why?
|
| Pulse Therapy, Drug | 1 | 2015 | 3 | 0.110 |
Why?
|
| Longitudinal Studies | 3 | 2015 | 651 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 76 | 0.110 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 31 | 0.110 |
Why?
|
| Cosmetic Techniques | 1 | 2014 | 4 | 0.110 |
Why?
|
| Physical Examination | 2 | 2022 | 37 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 143 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 18 | 0.110 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2014 | 1 | 0.100 |
Why?
|
| Microscopic Polyangiitis | 1 | 2014 | 1 | 0.100 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2014 | 2 | 0.100 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2014 | 2 | 0.100 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2014 | 3 | 0.100 |
Why?
|
| Interleukin-10 | 1 | 2014 | 11 | 0.100 |
Why?
|
| Adaptation, Psychological | 1 | 2014 | 83 | 0.100 |
Why?
|
| Interferon-alpha | 1 | 2014 | 15 | 0.100 |
Why?
|
| Creatinine | 1 | 2014 | 29 | 0.100 |
Why?
|
| B-Lymphocytes | 2 | 2019 | 25 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2014 | 48 | 0.100 |
Why?
|
| Renal Dialysis | 1 | 2014 | 37 | 0.100 |
Why?
|
| Liver Diseases | 1 | 2014 | 15 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 8 | 2004 | 69 | 0.100 |
Why?
|
| Body Height | 2 | 2004 | 8 | 0.100 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 449 | 0.100 |
Why?
|
| Abatacept | 2 | 2017 | 5 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor | 3 | 2009 | 10 | 0.100 |
Why?
|
| Cystitis | 1 | 1993 | 4 | 0.100 |
Why?
|
| Models, Biological | 2 | 2011 | 191 | 0.100 |
Why?
|
| Cultural Characteristics | 1 | 2013 | 14 | 0.100 |
Why?
|
| Incidence | 1 | 2014 | 338 | 0.090 |
Why?
|
| Matched-Pair Analysis | 1 | 2012 | 9 | 0.090 |
Why?
|
| Self-Assessment | 1 | 2012 | 11 | 0.090 |
Why?
|
| Self Concept | 1 | 2012 | 26 | 0.090 |
Why?
|
| Tenascin | 2 | 2002 | 2 | 0.090 |
Why?
|
| Sensation Disorders | 1 | 2012 | 8 | 0.090 |
Why?
|
| Antitubercular Agents | 2 | 2009 | 7 | 0.090 |
Why?
|
| Perception | 1 | 2012 | 42 | 0.090 |
Why?
|
| Menisci, Tibial | 1 | 2012 | 41 | 0.090 |
Why?
|
| Tuberculin Test | 2 | 2009 | 6 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 100 | 0.090 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2011 | 2 | 0.090 |
Why?
|
| Anterior Cruciate Ligament Injuries | 1 | 2012 | 80 | 0.080 |
Why?
|
| Tendon Injuries | 1 | 2012 | 81 | 0.080 |
Why?
|
| Orthopedic Procedures | 1 | 2012 | 111 | 0.080 |
Why?
|
| Braces | 1 | 2010 | 9 | 0.080 |
Why?
|
| Cytokines | 1 | 2011 | 107 | 0.080 |
Why?
|
| Teaching | 2 | 2022 | 29 | 0.080 |
Why?
|
| Pressure | 1 | 2010 | 24 | 0.080 |
Why?
|
| Sickness Impact Profile | 1 | 2010 | 6 | 0.080 |
Why?
|
| Social Environment | 1 | 2010 | 38 | 0.080 |
Why?
|
| Turkey | 2 | 2013 | 4 | 0.080 |
Why?
|
| Educational Status | 1 | 2010 | 130 | 0.080 |
Why?
|
| Self Report | 3 | 2015 | 94 | 0.070 |
Why?
|
| Extremities | 1 | 2008 | 10 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2011 | 817 | 0.070 |
Why?
|
| Adalimumab | 2 | 2019 | 10 | 0.070 |
Why?
|
| Rituximab | 1 | 2008 | 19 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 15 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 50 | 0.070 |
Why?
|
| Disability Evaluation | 2 | 2019 | 105 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2004 | 63 | 0.060 |
Why?
|
| Protein Kinase C-delta | 1 | 2007 | 5 | 0.060 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2007 | 13 | 0.060 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2007 | 7 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2007 | 23 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2004 | 157 | 0.060 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 182 | 0.060 |
Why?
|
| Prevalence | 2 | 2016 | 175 | 0.060 |
Why?
|
| Microscopy, Atomic Force | 1 | 2006 | 4 | 0.060 |
Why?
|
| Canada | 2 | 2018 | 21 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 73 | 0.060 |
Why?
|
| Body Weight | 2 | 2006 | 72 | 0.060 |
Why?
|
| DNA, Neoplasm | 2 | 2004 | 9 | 0.060 |
Why?
|
| Exercise Test | 1 | 2006 | 62 | 0.060 |
Why?
|
| Autoantigens | 1 | 2006 | 10 | 0.060 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2006 | 16 | 0.060 |
Why?
|
| Emotions | 2 | 2017 | 32 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2006 | 221 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2007 | 246 | 0.060 |
Why?
|
| Tibia | 1 | 2006 | 100 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2003 | 166 | 0.060 |
Why?
|
| Alcoholism | 1 | 2005 | 34 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 33 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2004 | 15 | 0.050 |
Why?
|
| Hypoxia | 1 | 2004 | 14 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 41 | 0.050 |
Why?
|
| Abstracting and Indexing as Topic | 1 | 2004 | 1 | 0.050 |
Why?
|
| MEDLINE | 1 | 2004 | 1 | 0.050 |
Why?
|
| Therapeutic Irrigation | 1 | 2004 | 27 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2004 | 26 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2004 | 15 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2004 | 105 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 128 | 0.050 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 2003 | 2 | 0.050 |
Why?
|
| Peritonitis | 1 | 2003 | 10 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2001 | 19 | 0.050 |
Why?
|
| Femur Head | 1 | 2003 | 20 | 0.050 |
Why?
|
| Biopsy | 1 | 2003 | 97 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2003 | 58 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 464 | 0.050 |
Why?
|
| Internal Medicine | 1 | 2022 | 13 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2002 | 22 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2007 | 275 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2002 | 28 | 0.040 |
Why?
|
| Vaccination | 1 | 2021 | 9 | 0.040 |
Why?
|
| Fibronectins | 1 | 2001 | 10 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2022 | 96 | 0.040 |
Why?
|
| Alendronate | 1 | 2001 | 4 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2001 | 5 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 2001 | 5 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2001 | 29 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 21 | 0.040 |
Why?
|
| Spinal Fractures | 1 | 2001 | 25 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2000 | 125 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2019 | 38 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2019 | 15 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2019 | 14 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2019 | 49 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 16 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 151 | 0.040 |
Why?
|
| Hip | 1 | 1999 | 16 | 0.040 |
Why?
|
| Femur Neck | 1 | 1999 | 11 | 0.040 |
Why?
|
| Mentors | 1 | 2019 | 16 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 6 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 21 | 0.040 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2002 | 264 | 0.040 |
Why?
|
| Morbidity | 1 | 2018 | 33 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2018 | 6 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2018 | 34 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2019 | 27 | 0.040 |
Why?
|
| Workload | 1 | 2018 | 12 | 0.040 |
Why?
|
| Somatosensory Disorders | 1 | 2018 | 5 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2019 | 34 | 0.030 |
Why?
|
| Aging | 1 | 2003 | 680 | 0.030 |
Why?
|
| Independent Living | 1 | 2019 | 137 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 338 | 0.030 |
Why?
|
| Blood Sedimentation | 1 | 2017 | 26 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2017 | 39 | 0.030 |
Why?
|
| Mental Health | 1 | 2017 | 47 | 0.030 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2017 | 45 | 0.030 |
Why?
|
| Illinois | 1 | 2017 | 110 | 0.030 |
Why?
|
| Osteonecrosis | 1 | 2017 | 9 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 18 | 0.030 |
Why?
|
| Exercise | 1 | 2019 | 233 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 40 | 0.030 |
Why?
|
| Mice | 1 | 2019 | 760 | 0.030 |
Why?
|
| Schizosaccharomyces pombe Proteins | 1 | 1996 | 1 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1996 | 5 | 0.030 |
Why?
|
| Endopeptidases | 1 | 1996 | 12 | 0.030 |
Why?
|
| Checklist | 1 | 2016 | 16 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 24 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 1996 | 45 | 0.030 |
Why?
|
| Sleep | 1 | 2017 | 155 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 141 | 0.030 |
Why?
|
| Chromatography, Ion Exchange | 2 | 1994 | 3 | 0.030 |
Why?
|
| Software | 1 | 2015 | 26 | 0.030 |
Why?
|
| Physicians | 1 | 2015 | 43 | 0.030 |
Why?
|
| Goals | 1 | 2014 | 24 | 0.030 |
Why?
|
| Arthrography | 2 | 2006 | 12 | 0.030 |
Why?
|
| Collagen | 1 | 1994 | 44 | 0.030 |
Why?
|
| Translations | 1 | 2013 | 2 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2004 | 57 | 0.020 |
Why?
|
| Culture | 1 | 2013 | 10 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2013 | 26 | 0.020 |
Why?
|
| Polyarteritis Nodosa | 1 | 1993 | 1 | 0.020 |
Why?
|
| Necrosis | 1 | 1993 | 10 | 0.020 |
Why?
|
| Hemorrhage | 1 | 1993 | 30 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2004 | 60 | 0.020 |
Why?
|
| Philippines | 1 | 2013 | 3 | 0.020 |
Why?
|
| Phenotype | 3 | 2004 | 157 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2003 | 171 | 0.020 |
Why?
|
| Chondroitin Lyases | 1 | 1992 | 1 | 0.020 |
Why?
|
| Chymotrypsin | 1 | 1992 | 2 | 0.020 |
Why?
|
| Chromatography, Gel | 1 | 1992 | 3 | 0.020 |
Why?
|
| Trypsin | 1 | 1992 | 4 | 0.020 |
Why?
|
| Electrochemistry | 1 | 1992 | 29 | 0.020 |
Why?
|
| Denmark | 1 | 2012 | 4 | 0.020 |
Why?
|
| Sweden | 1 | 2012 | 7 | 0.020 |
Why?
|
| Alternative Splicing | 2 | 2002 | 8 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 1991 | 9 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1991 | 28 | 0.020 |
Why?
|
| Metabolism | 1 | 2011 | 4 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 47 | 0.020 |
Why?
|
| Cell Line | 1 | 1991 | 150 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2011 | 42 | 0.020 |
Why?
|
| Femoral Neoplasms | 1 | 1990 | 2 | 0.020 |
Why?
|
| Cognition | 1 | 2014 | 641 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2007 | 17 | 0.020 |
Why?
|
| Arteries | 1 | 2007 | 11 | 0.020 |
Why?
|
| Risk | 2 | 2004 | 97 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 19 | 0.020 |
Why?
|
| Viscosity | 1 | 2006 | 6 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2007 | 64 | 0.020 |
Why?
|
| Elasticity | 1 | 2006 | 19 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 53 | 0.020 |
Why?
|
| Actins | 1 | 2006 | 18 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 34 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2006 | 46 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2006 | 128 | 0.020 |
Why?
|
| Posture | 1 | 2006 | 20 | 0.020 |
Why?
|
| Models, Anatomic | 1 | 2006 | 19 | 0.010 |
Why?
|
| Movement | 1 | 2006 | 58 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2004 | 6 | 0.010 |
Why?
|
| Genes, myc | 1 | 2004 | 8 | 0.010 |
Why?
|
| Genome | 1 | 2004 | 4 | 0.010 |
Why?
|
| Child | 2 | 2004 | 614 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2004 | 3 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 15 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2004 | 45 | 0.010 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2004 | 3 | 0.010 |
Why?
|
| Information Storage and Retrieval | 1 | 2004 | 2 | 0.010 |
Why?
|
| Infliximab | 1 | 2004 | 7 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 89 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 84 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 56 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2002 | 22 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 62 | 0.010 |
Why?
|
| K562 Cells | 1 | 2002 | 4 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 13 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2002 | 25 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 57 | 0.010 |
Why?
|
| Plasma Exchange | 1 | 1982 | 2 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 80 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 100 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2002 | 42 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2001 | 22 | 0.010 |
Why?
|
| Binding Sites | 1 | 2001 | 39 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2001 | 1 | 0.010 |
Why?
|
| Genes, p16 | 1 | 2001 | 4 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2001 | 12 | 0.010 |
Why?
|
| Placebos | 1 | 2001 | 25 | 0.010 |
Why?
|
| Reoperation | 1 | 2002 | 366 | 0.010 |
Why?
|
| Bone Resorption | 1 | 2001 | 55 | 0.010 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 1996 | 1 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1996 | 2 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1996 | 4 | 0.010 |
Why?
|
| Ploidies | 1 | 1996 | 4 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 30 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1996 | 7 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 1999 | 182 | 0.010 |
Why?
|
| Fees, Medical | 1 | 1975 | 1 | 0.010 |
Why?
|
| Public Opinion | 1 | 1975 | 1 | 0.010 |
Why?
|
| Financing, Organized | 1 | 1975 | 4 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 1975 | 62 | 0.010 |
Why?
|
| Orchiectomy | 1 | 1994 | 2 | 0.010 |
Why?
|
| Tritium | 1 | 1994 | 4 | 0.010 |
Why?
|
| Sulfur Radioisotopes | 1 | 1994 | 3 | 0.010 |
Why?
|
| Hexuronic Acids | 1 | 1994 | 4 | 0.010 |
Why?
|
| Glucuronic Acid | 1 | 1994 | 4 | 0.010 |
Why?
|
| Sulfates | 1 | 1994 | 2 | 0.010 |
Why?
|
| Alginates | 1 | 1994 | 5 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1994 | 11 | 0.010 |
Why?
|
| Proline | 1 | 1994 | 5 | 0.010 |
Why?
|
| Gels | 1 | 1994 | 7 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1994 | 35 | 0.010 |
Why?
|
| Cattle | 1 | 1994 | 54 | 0.010 |
Why?
|
| Clone Cells | 1 | 1990 | 8 | 0.000 |
Why?
|
| Antithrombin III | 1 | 1982 | 1 | 0.000 |
Why?
|
| Plasminogen | 1 | 1982 | 1 | 0.000 |
Why?
|
| Plasmapheresis | 1 | 1982 | 6 | 0.000 |
Why?
|
| Hemostasis | 1 | 1982 | 7 | 0.000 |
Why?
|
| Blood Coagulation Factors | 1 | 1982 | 10 | 0.000 |
Why?
|
| Thrombosis | 1 | 1982 | 33 | 0.000 |
Why?
|
| New York | 1 | 1975 | 2 | 0.000 |
Why?
|
| Financing, Government | 1 | 1975 | 3 | 0.000 |
Why?
|
| Attitude | 1 | 1975 | 14 | 0.000 |
Why?
|
| Consumer Behavior | 1 | 1975 | 14 | 0.000 |
Why?
|